Impact of the Routine Collection of Symptoms on Quality of Life in Dialysis Patients (FSWIFT-PILOT)

February 25, 2025 updated by: Carole AYAV, Central Hospital, Nancy, France

Impact on the Quality of Life of Dialysis Patients of the Routine Collection of Symptoms by the Patients Themselves, with Feedback to the Dialysis Team - Pilot Study

Chronic kidney disease (CKD) affects 85,000 people in France. Medical care for this disease represents 2% of the Health Insurance budget.

Patients on dialysis frequently experience severe or overwhelming symptoms which contributes to poor health related quality of life (HRQoL). However, taking into account the measurement of the patients' symptoms by the patients themselves would allow to improve their HRQoL by putting more emphasis on the results that matter the most to the patients. It would also improve information and decision-making between nephrology care team and patients.

Systematic use of patients reported outcomes measures (PROMs) is not widely used due to a number of barriers including logistics and feasibility.

How will the F-SWIFT Pilot project address the barriers associated with PROMs? By choosing short questionnaires to complete By providing feedback on the severity of symptoms to the dialysis team and to patients By making links to good practice recommendations included in the feedback Allowing electronic collection of PROMs The research question therefore asks whether regular symptom monitoring with feedback to dialysis staff improves dialysis patient's outcomes? To do this, a pilot study must be carried out with the following main objectives Test the feasibility of integrating electronic measurements of PROMs with feedback to the dialysis team.

Three centers are participating in this pilot study:

  • The nephrology department of the Nancy CHRU
  • The Lorraine Association for the Treatment of Renal Insufficiency (ALTIR)
  • The nephrology department of the Nîmes University Hospital

The project will take place in 2 phases :

Phase 1 To identify the needs and expectations of patients and health professionals in relation to a systematic electronic measurement of symptoms made by the patients themselves.

Focus groups (interviews) will be conducted with patients (n=15) and healthcare professionals (n=15).

Phase 2 (n=50-60 patients) To develop and test an electronic PROMs system allowing

  • Collect patients' symptoms
  • Identify patients with severe symptoms
  • Alert the dialysis team in case of severe symptoms
  • Suggest appropriate management strategies

Study Overview

Status

Terminated

Conditions

Detailed Description

Patients reported outcomes (PROs) are defined as any measure of a patient's health status reported directly by the patient, without interpretation by health care professionals or others. It is how the patient feels about their health condition or treatment. Although assessing patients' well-being and managing their symptoms are the foundations of clinical care, the care patients receive often does not meet their needs. For example, healthcare professionals are often unaware of the presence and severity of their patients' symptoms. The integration of PROs into clinical trials, clinical care, and quality of care assessment stems from the need to place greater emphasis on the outcomes that matter most to patients.

To date, primary clinical trial endpoints and efficacy metrics in nephrology have been dominated by objective biochemical and process measures (percentage of patients with arteriovenous fistula). These measures fail to reflect what constitutes a good outcome from the patient's perspective, and ultimately there is often very little information about how treatments or any other interventions affect the patient's experience A growing number of studies report a high frequency of symptoms in adult dialysis patients. Patients frequently present with signs of severe pain, fatigue, nausea, cramping, itching, sleep disturbance, and depression, which are strongly associated with poor quality of life. More than half of patients experience fatigue, pruritus (relentless itching), and constipation despite available effective treatments.

In nephrology, studies have focused on survival or biomarker studies and very little on interventions to improve what was a priority for patients, i.e., treating their symptoms and improving their quality of life.

Numerous experiments have been conducted in other fields such as oncology. These studies have shown a real benefit of taking into account measures of perceived health on improving symptom management, treatment side effects and patient survival. Patients for whom regular perceived health follow-up with feedback to oncologists is implemented have a better survival than with traditional follow-up. This is mainly explained by earlier identification and management of symptoms (preventing or reducing the occurrence of downstream adverse events) or side effects of chemotherapy (allowing better tolerance and adherence to the full chemotherapy regimen).

Patients with end-stage renal disease (ESRD) treated with dialysis have poorer survival than patients with certain cancers and a particularly degraded quality of life. Symptoms reported by dialysis patients are often underestimated or even unrecognized by the dialysis team for a variety of reasons. Therefore, it seems possible to improve patient management, outcome, and quality of life through better consideration of symptoms provided the dialysis team is aware of them.

Many questions are still open. Which PRO to measure? How should it be measured? How to store and use the data? How to interpret the results? How can they be integrated with other measures in patient management and treatment decisions? The impact of routine PRO measurements is controversial, especially because of methodological biases in the various studies.

A clinical trial will be set up and nested in the national RIEN registry, entitled F-SWIFT (French-Symptom monitoring WIth Feedback Trial) to improve symptom management in order to address the unmet needs of dialysis CKD patients and improve their quality of life.

The research question posed is whether regular self-reported symptom monitoring with immediate feedback and management recommendations to the dialysis team improves the outcome of dialysis patients.

The F-SWIFT study is the French side of the Australian SWIFT study which has obtained funding and started in 2019.

irst, some technical and logistical feasibility questions need to be answered to adapt the SWIFT study to the French context. Indeed, to date, the PRO measurement is not a routine measurement in dialysis facilities. It therefore seems important to approach patients and professionals to explore their expectations and needs in terms of integrating PRO as a routine management indicator. The first phase is therefore the realization of a pilot study, which is the subject of this protocol.

Study Type

Observational

Enrollment (Actual)

65

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Vandoeuvre-les-Nancy, France, 54500
        • CHRU de NANCY

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

  • For the first part
  • Patients of both sexes, of different ages and treated by dialysis (hemodialysis and peritoneal dialysis) in different structures (heavy center, medicalized dialysis unit, self-dialysis, home).
  • Health professionals: nephrologist, health executive, dialysis nurse and nurse coordinator (IPA advanced practice nurse), nursing assistants.
  • For the second part
  • Adult patients, volunteers and dialyzed in one of the participating centers: the two heavy centers of the CHRU of Nancy and Nîmes and the off-center dialysis units of ALTIR,
  • For the pilot phase, we plan to include between 50 and 60 patients (10 per heavy center, 15 in MDU, 15 in AD and 15 at home)

Translated with www.DeepL.com/Translator (free version)

Description

Inclusion Criteria:

  • For the focus group phase:

Patients

  • Adult patients (≥ 18 years of age), volunteers with end-stage renal disease (ESRD) treated by dialysis in the study centers
  • Individuals who have received complete information on the organization of the research and who have not objected to their participation and to the use of their data
  • Person with internet access and a computer tool such as a tablet, computer or smartphone

Health professionals - Volunteer healthcare professionals in the participating departments (CHRU Nancy, ALTIR, CHU Nîmes) with at least 3 months experience in a dialysis department

For the test phase of symptom collection in dialysis services:

  • Adult patients (≥ 18 years of age), volunteers with end-stage chronic kidney disease (ESRD) treated with dialysis for at least 3 months in the study participating centers
  • Person who has received full information on the organization of the research and has not objected to his or her participation and to the use of his or her data
  • Patient able to answer a self-questionnaire
  • Person with internet access and a computer tool such as a tablet, computer or smartphone
  • Person able to use a computer tool such as a tablet or smartphone
  • Person affiliated to a social security system

Exclusion Criteria:

The non-inclusion criteria for the focus group phase are as follows :

Patients

  • Non-dialysis patient
  • Dialysis patient in retreat at the facility
  • Patient dialyzed for less than 3 months
  • Non-voluntary patient
  • Minor patient
  • Patient who does not speak French
  • Person placed under judicial protection, guardianship or curatorship

Health Professionals

- Non-voluntary health professional

The non-inclusion criteria for the test phase of the collection are as follows:

  • Non-dialysis patient
  • Dialysis patient in retreat at the facility
  • Patient dialyzed for less than 3 months
  • Non-voluntary patient
  • Minor patient
  • Person placed under court protection, guardianship or curatorship

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Patient Group - Phase 1
15 to 30 patients are expected in Phase 1 for the identification of needs and expectations in relation to a systematic electronic assessment of symptoms by the patients themselves
Health Professionals Group - Phase 1
15 to 30 healthcare professionals are expected to participate in Phase 1 regarding the identification of needs and expectations in relation to a systematic electronic assessment of symptoms by the patients themselves
Patient Group - Phase 2
50 à 60 patients were expected to test a systematic electronic assessment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The feasibility of integrating electronic measurements of self-perceived symptoms with feedback to the dialysis team.
Time Frame: 11 months

Feasability will be assessed through interviews with patients and health professionals. These interviews will help to identify the elements (interest in the measurement of symptoms by the patients themselves, type of symptoms to be collected, time of measurement, frequency of repetition of the measurement, alert threshold, management of alerts, management of reminders, recommendations for management, etc.) that will guarantee good acceptability of the integration of these measures.

The feasibility will be apprehended by a test phase of the measurement of the symptoms perceived by the patients in real situation using a questionnaire given to the patients and the health professionals.
11 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Results of the focus groups with patients and health professionals
Time Frame: 2 months
Identify the needs and expectations of patients and health care professionals with respect to a systematic electronic assessment of symptoms by patients themselves
2 months
Creation of the electronic symptom collection tool, implementation of links with the REIN registry, systems for managing reminders, alerts, reporting and referrals to management recommendations
Time Frame: 6 months

Develop the IT tool and interface allowing :

  • the link with DIADEM* (secure connection, identity vigilance, integration of the perceived health measure in the registry),
  • the collection of symptoms,
  • identification of patients with severe symptoms,
  • alerting the dialysis team in case of severe symptoms,
  • the concomitant proposal of adapted management strategies
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Central Hospital, Nancy, France

Collaborators

Agence de La Biomédecine
Association France REIN

Investigators

  • Principal Investigator: Luc FRIMAT, CHRU de NANCY
  • Principal Investigator: Olivier Moranne, Centre Hospitalier Universitaire de Nîmes
  • Principal Investigator: Nelly CASTIN, ALTIR

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 27, 2022

Primary Completion (Actual)

November 13, 2023

Study Completion (Actual)

February 22, 2024

Study Registration Dates

First Submitted

November 15, 2021

First Submitted That Met QC Criteria

December 10, 2021

First Posted (Actual)

December 13, 2021

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 25, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2021-A00776-35

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Patients Reported Outcomes

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe